Company Overview and News
SAN JOSE, Calif., Oct. 08, 2018 (GLOBE NEWSWIRE) -- Energous Corporation [NASDAQ: WATT], the developer of WattUp®, a revolutionary wireless charging 2.0 technology, today announced that it was selected by SK Telesys to exclusively demonstrate its award-winning WattUp wireless charging technology at the SK ICT Tech Summit on October 31, 2018.
2018-10-08 globenewswire - 8
THOROFARE, N.J., Oct. 08, 2018 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (“Akers Bio” or the "Company"), a developer of rapid health information technologies, announces a leadership change, an update to the Company’s business strategy, the settlement of its lawsuit with Pulse Health LLC (“Pulse Health”) and the resignation of its Nominated Adviser on the London Stock Exchange’s AIM market.
SSFN AKR PROM PHG LNSTY WATT TE AKER
2018-09-10 seekingalpha - 4
Thanks for joining us today! Welcome to Dr Zach Hartman and Amit Ghate, two well-known analysts on SeekingAlpha, and very luckily for us here at the Total Pharma Tracker, our two outstanding collaborators.
VTL MNKD TSRO EXEL NVCR GERN XNET TLRY BGNE AERI WATT RDUS
As part of its global regulatory campaign, the company reaches a major milestone as WattUp is approved to ship in 100 countries including the U.S., United Kingdom, European Union, Taiwan, India, Australia and Canada
Registration Statement on Form S-3 Table of Contents As filed with the Securities and Exchange Commission on August 9, 2018 Registration No. 333-
watt-10q_20180630.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION
SAN JOSE, Calif., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Energous Corporation (NASDAQ:WATT), the developer of WattUp®, a revolutionary wire-free, power-at-a-distance charging technology, today announced that Brian Sereda, chief financial officer, will present a company overview at the Oppenheimer 21st Annual Technology, Internet & Communications Conference on Wednesday, Aug. 8, 2018 at 1:45 p.m. ET at the Four Seasons Hotel, in Boston, MA.
Energous (WATT - Free Report) just came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to loss of $0.63 per share a year ago. These figures are adjusted for non-recurring items.
BRK.A XOM O OPRF WATT HUBG HUBOF
2018-07-25 investorplace - 9
There’s a fundamental mathematical proposition that makes shorting stocks risky. A short sale — a sale of borrowed stock, made with the intention of buying it back at a cheaper price later — in theory has unlimited losses. A long investor can only lose 100% of her money at most. But a short could lose multiples of the capital originally at risk.
MDGL FB POSTZ SPWR POSTU SKT NFLX AXDX] HRI SIRI MTCH AMZN SPOT AABA AAPL WATT DIS BGS OSTK RDEN SYNA AMC IAC P AXDX ICPT DLGNF PLCE CAR W REV POST MAT BABA HAS T ATHM POSHZ BITA TSLA VZ AAOI STRP DPZ HTZ TUES PZZA
2018-06-28 globenewswire - 2
Cost-effective, production-ready transmitter solution supports a variety of customer applications including hearing aids, fitness trackers, smartwatches, wireless earbuds and more
2018-06-22 bloomberg - 6
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to WATT / Energous Corporation on message board site Silicon Investor.
as of ET